Individuals enrolled in Apple Health (Medicaid), Public Employees Benefits Board, and School Employees Benefits Board coverage - and those accessing behavioral health services - will not experience a disruption in care due to the federal government shutdown. In addition, health care providers will continue to be paid for the services they provide. We will continue to monitor the situation closely and share updates if anything changes.
Viscosupplementation, which involves an injection of hyaluronic acid (HA), provides an alternative to NSAIDs and corticosteroid injection, both of which have potential undesirable side effects and/or other drawbacks. HA is a normal component of synovial fluid and cartilage that acts as both a joint lubricant and a shock absorber.
Status: Decision completed
Hyaluronic acid preparations have been approved by the Food and Drug Administration (FDA) for treatment of pain associated with osteoarthritis (OA) of the knee in patients who have not had an adequate response to nonpharmacological, conservative treatment and simple analgesics. No new indications have been approved since the 2010 report.
| Type | Materials |
|---|---|
| Assessment (2023) | |
| Assessment (2013) | |
| Assessment (2010) |
All future dates are estimates and subject to change.
